Ovarian Cancer gets Orphan Drugs as ZW25 and ZW33; approves FDA

Release Date: 17-Oct-2016

Zymeworks, a pharmaceutical company, announces that Food and Drug Association (FDA) has granted orphan drug designation to ZW25 and ZW33 for effective treatment of ovarian cancer.


ZW25 is a novel bispecific antibody designed to target two different epitopes of the HER-2 protein, overexpressed on the surface of several tumor types, including ovarian, lung, breast and gastric cancers. ZW33 is a drug-conjugated version of ZW25.The Company is looking for better possible treatment followed best results in patients suffering from ovarian cancer.


For Orphan Drug Clinical Insight Reports Contact:  neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.